08 Sep 2023

Xbrane announces that members of Xbrane’s management team have sold shares for tax purposes.

29 Aug 2023

Xbrane Biopharma releases interim report for January – June 2023

29 Aug 2023

XBRANE UPDATES AMBITION TO GENERATE POSITIVE OPERATING CASH FLOW ON AN MONTHLY BASIS BEFORE END OF FIRST QUARTER 2025

25 Aug 2023

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2023 on August 29, 2023

25 Jul 2023

Xbrane invites to a webcast today Tuesday, July 25th, 2023

25 Jul 2023

STADA and Xbrane weigh options for ranibizumab biosimilar candidate

21 Jun 2023

Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate

15 Jun 2023

Xbrane strengthens its commitment to sustainable business by joining the United Nations Global Compact

31 May 2023

Xbrane Biopharma releases interim report for January – March 2023

31 May 2023

Change of number of shares and votes in Xbrane

29 May 2023

Correction: Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023

29 May 2023

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2023 on May 31, 2023

26 May 2023

STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany

23 May 2023

Xbrane has carried out a directed share issue and an issue of convertible bonds raising gross proceeds of approximately SEK 350 million

22 May 2023

Xbrane announces its intention to carry out a directed share issue and an issue of convertible bonds totaling approximately SEK 325 million in financing